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ABSTRACT 
 
 
Using the biochemically tractable Xenopus oocyte model system, we have 
previously characterized a novel metabolic regulation of cell death. We found that 
glucose-6-phosphate (G6P) via the pentose phosphate pathway leads to increased 
nicotinamide adenine dinucleotide phosphate (NADPH) levels, a subsequent increase in 
cytosolic acetyl-coenzyme A and activation of Ca2+/calmodulin-dependent protein kinase 
II (CaMKII). We recently identified coenzyme A (CoA), derived from the breakdown of 
acetyl-CoA, as the key metabolic signal that mediates a novel mechanism of calmodulin-
dependent activation of CaMKII. CoA binds directly to the calmodulin (CaM) binding 
domain (CaMBD) of CaMKII resulting in its activation and downstream inhibitory 
phosphorylation of caspase-2, suppressing apoptosis. In this dissertation, we questioned 
whether there are other CaMBD containing proteins metabolically regulated by CoA. In 
an unbiased approach, CaM binding proteins were first isolated from Xenopus extract 
using a CaM-Sepharose column. Purified CaM binding proteins were then incubated with 
CoA-Sepharose in a second purification step and resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining. The results indicate 
the presence of numerous CaM-binding proteins that also bind CoA and are thus 
potentially metabolically regulated. In a targeted approach, we tested the ability of 
aberrant glucose signaling to regulate the CaM-binding protein PI3K. We found that 
addition of G6P, mimicking aberrant glucose metabolism, or CoA to X. laevis egg 
extracts activated Akt in a phosphatidylinositol 3-kinase (PI3K), phosphoinositide-
dependent protein kinase 1(PDPK1)-dependent manner. Additionally, we show that CoA 
binds directly to and activates PI3K.  These findings uncover a novel mechanism of PI3K 
activation by aberrant glucose metabolism and suggest a potentially unknown constitutive 
activation pathway of PI3K/Akt by aberrant glucose signaling. 
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CHAPTER 1.    INTRODUCTION 
 
 
Altered Metabolism Is a Hallmark of Cancer 
 
Cancer is a disease of uncontrolled cellular growth with the potential to 
metastasize to other tissues and organs (1). Understanding the cellular signaling pathways 
that become dysregulated and underlie the transformation of a normal cell to a cancer cell 
with limitless proliferative capacity is pivotal to develop effective treatments. Although 
cancer is a highly heterogenous disease, the physiological effects of such altered 
signaling pathways summarize the core hallmarks of cancer cells: anti-growth signals, 
self-sufficiency in growth signals, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, metastasis, immune system evasion, unstable DNA, inflammation 
and dysregulated metabolism (2, 3). Our focus here is on the altered metabolism of tumor 
cells and its regulation of major signaling pathways. 
 
Cellular metabolism is significantly rewired in cancer cells to support their rapid 
proliferation and continuous growth. In a normal cell, nutrient uptake and metabolism is 
tightly regulated, preventing abnormal proliferation (4). Cancer cells circumvent these 
metabolic control systems through the acquisition of genetic mutations in key tumor 
suppressors and oncogenes (5). Such metabolic reprogramming, while heterogenous 
across tumor cells, serves a common purpose in providing: sufficient energy (ATP and 
NADPH), building blocks to synthesize macromolecules, and reducing agents to counter 
high production of reactive oxygen species (ROS) (6). Some of the major metabolic 
alterations found in tumor cells that support the bioenergetic demands of their excessive 
growth include increased glycolysis, elevated amino acid and lipid metabolism, increased 
glutaminolysis, enhanced mitochondrial biogenesis, and induction of the pentose 
phosphate pathway (7). Here, we focus on the coordinated increase in glycolysis and the 
pentose phosphate pathway that supports the limitless proliferative capacity of tumor 
cells.  
 
 
The Warburg Effect 
 
First characterized by Dr. Otto Warburg and hence referred to as the “Warburg 
effect,” cancer cells preferentially catabolize glucose via glycolysis even in the presence 
of oxygen (8-10). In a normal cell, glucose is completely oxidized via glycolysis, the 
tricarboxylic acid (TCA) cycle, and mitochondrial oxidative phosphorylation to produce 
an optimal yield of 36 ATP molecules for each molecule of glucose. While normal cells 
prioritize glycolysis only under anaerobic conditions (7), cancer cells preferentially 
metabolize glucose to pyruvate via glycolysis followed by its conversion to lactate. This 
circumvention of the TCA cycle and mitochondrial oxidative phosphorylation yields only 
2 molecules of ATP per each molecule of glucose. However, tumor cells compensate for 
this by increasing glucose uptake and elevating the expression as well as the activity of 
glycolytic enzymes.  
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One of the major features distinguishing tumor cells from normal cells is their 
increased uptake of glucose mediated by an upregulation of glucose transporters (11-14). 
Indeed, this difference allows for the visualization of tumors by Positron Emission 
Tomography (PET) using radiolabeled glucose analogs such as 18F-fluorodeoxyglucose 
as tracers (7). With a greater amount of substrate available for glycolysis, tumor cells 
concomitantly increase the expression and activity of glycolytic enzymes, together 
supporting an enhanced glycolytic flux.  
 
 The elevated expression and activity of glycolytic enzymes in cancer cells is 
mediated by enhanced transcriptional activity of hypoxia inducible factor-1 (HIF1) and 
Myc as well as loss of p53-mediated control (7). HIF1 is elevated in many cancers 
through gain of function mutations in major oncogenes such as phosphatidylinositol 3-
kinase/Akt, Ras, and human epidermal growth factor receptor (HER) as well as through 
the loss of key tumor suppressors p53, von Hippel-Lindau (pVHL), and phosphatase and 
tensin homolog (PTEN), the negative regulator of the PI3K/Akt axis (15). The oncogene 
MYC encodes a transcription factor responsible for regulating a vast number of human 
genes involved in cell cycle, metabolism, ribosome biogenesis, apoptosis and 
transformation (15). In terms of the Warburg effect, Myc and HIF1 promote the 
expression of glucose transporters as well as key glycolytic enzymes including 
hexokinase 2 (HK2), phosphofructokinase-1 (PFK1), triosephosphate isomerase-1 (TPI1) 
and lactate dehydrogenase A (LDHA), among others (4, 11, 16-20). Myc also mediates 
the enhanced glutaminolysis observed in many cancer cells (21).  
 
In contrast, the tumor suppressor p53 downregulates HK2 expression while 
enhancing expression of TP53-induced glycolysis and apoptosis regulator (TIGAR), 
synthesis of cytochrome c oxidase 2 (SCO2) and apoptosis-inducing factor (AIF) (22). 
TIGAR via dephosphorylation, reduces the levels of fructose-2, 6-bisphosphate, an 
important allosteric activator of the key glycolytic enzyme PFK1 (23). SCO2 regulates 
the cytochrome c oxidase complex, promoting mitochondrial respiration (5) while AIF is 
vital for the function of complex I in the electron transport chain (24). p53 also 
suppresses glucose uptake by directly inhibiting the transcription of glucose transporters 
Glut1 and Glut4 (25, 26) and suppressing the expression of Glut3 (26). The net effects of 
wild-type p53 are therefore to decrease glycolytic flux and promote mitochondrial 
oxidative phosphorylation (22, 27). In addition, p53 is a negative regulator of HIF1 (28) 
while HIF1 is an enhancer of Myc transcription (18). Together, p53, Myc and HIF1 
constitute an interconnected triad of master transcription factors responsible for the 
altered glycolytic phenotype observed in tumor cells (16, 18, 29).  
 
While normal cells, under aerobic conditions, convert the glycolytic end-product 
pyruvate to acetyl-CoA to fuel the TCA cycle, tumor cells preferentially convert pyruvate 
to lactate even in the presence of oxygen due to an upregulation of LDHA, mediated by 
Myc and HIF1 (18). In addition, Myc and HIF1 also induce expression of pyruvate 
dehydrogenase kinase 1 (PDK1) (18), a negative regulator of pyruvate dehydrogenase 
(PDH), the first component enzyme of the pyruvate dehydrogenase complex, responsible 
for the conversion of pyruvate to acetyl-CoA. The net result is an increased production of 
lactate and a circumvention of the TCA cycle and mitochondrial oxidative 
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phosphorylation. The preferential conversion of pyruvate to lactate, mediated by LDHA 
overexpression, allows tumor cells to rapidly regenerate the nicotinamide adenine 
dinucleotide (NAD+) consumed by glycolysis and thus supports an accelerated glycolytic 
rate (11, 16, 17, 19, 30). Indeed, LDHA is upregulated in a diverse array of human 
cancers including pancreatic cancer (31), hepatocellular carcinoma (32), breast cancer 
(33), esophageal squamous cell carcinoma (34) and prostate cancer (35), and its 
overexpression has been linked to tumor initiation, growth and maintenance (36). 
Furthermore, the excretion of lactate lowers the extracellular pH which enhances the 
activity of metalloproteases to break down extracellular matrix and ultimately facilitate 
cancer invasion and metastasis (37, 38).  
 
Thus, despite producing significantly less ATP per each molecule of glucose, 
tumor cells compensate by increasing glucose uptake, rapidly regenerating NAD+, and 
ultimately enhancing glycolytic flux. Importantly, this provides tumor cells not only with 
energy in the form of ATP, but also key glycolytic intermediates which are necessary 
precursors for biosynthesis (7). For instance, G6P can enter the pentose phosphate 
pathway to generate ribose-5-phosphate (R5P), an important precursor to many 
biomolecules including nucleotides (5), as well as NADPH which is required for 
reductive anabolic biosynthesis and redox balance. Dihydroxacetone phosphate generated 
in glycolysis can be used to synthesize lipids required for cell growth and division (7). 
Additionally, the amino acids serine, cysteine and glycine are generated from the 
glycolytic intermediate 3-phosphoglycerate (39). In this manner, the metabolic rewiring 
observed in tumor cells provides a significant proliferative advantage by allowing for the 
accumulation of important glycolytic intermediates necessary for cell growth, DNA 
replication, and cell division.  
 
 
The PI3K/Akt/mTORC1 Pathway 
 
 The PI3K pathway is a vital signal transduction system that links multiple 
receptor classes to a diverse array of essential cellular functions including metabolism, 
inflammation, cell survival, growth, motility and apoptosis (40). While three distinct 
classes of PI3K exist, the class IA PI3Ks have been implicated in cancer (41) and will be 
the focus here. Class IA PI3Ks are heterodimers comprised of a catalytic p110 subunit 
and a regulatory p85 subunit. The three members of this class, p110/p85, p110/p85 
and p110/p85, are activated downstream of receptor tyrosine kinases (RTKs) (Figure  
1-1) as well as G-protein coupled receptors (GPCRs) in the case of p110/p85 and 
p110/p85. Focusing on the former, upon growth factor binding and subsequent 
activation of RTKs, PI3K is recruited to the membrane via binding of the p85 regulatory 
subunit directly to phosphorylated tyrosine residues on the cytoplasmic domain of the 
activated RTK (e.g. platelet derived growth factor receptor [PDGFR]) or on an adaptor 
protein recruited to and phosphorylated by the RTK (e.g. epidermal growth factor 
receptor [EGFR], HER2, insulin receptor [InsR], fibroblast growth factor receptor 
[FGFR]) (41). This binding not only recruits PI3K to its lipid substrate, 
phosphatidylinositol-4,5-bisphosphate (PIP2), at the plasma membrane, it also relieves  
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Figure 1-1 Canonical activation of class IA PI3K by RTKs. 
Growth factor binds and activates its respective receptor tyrosine kinase (RTK). 
Activated RTK (e.g. FGFR, HER2, EGFR) recruits and phosphorylates an adaptor 
protein which in turn recruits class IA PI3K via binding the N-terminal SH2 domain of its 
p85 regulatory subunit. Activated RTK (e.g. PDGFR) can also directly bind the p85 
subunit (not shown). Binding of the p85 regulatory subunit relieves its allosteric 
inhibition on the p110 catalytic subunit. Active PI3K catalyzes the phosphorylation of 
PIP2 to PIP3. The second messenger PIP3 recruits Akt and PDPK1 to the membrane via 
their respective pleckstrin homology domain. PDPK1 phosphorylates T308 of Akt and 
mammalian target of rapamycin complex 2 (mTORC2) phosphorylates S473 of Akt, 
resulting in full activation of Akt. The tumor suppressor PTEN negatively regulates PI3K 
signaling by catalyzing the dephosphorylation of PIP3 back to PIP2.  
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the allosteric inhibition of the p85 regulatory subunit on the p110 catalytic subunit (42). 
PIP2 is then phosphorylated by the p110 subunit to produce the second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3). PTEN dephosphorylates PIP3 at the 3’ 
position of the inositol ring and is thus a vital negative regulator of PI3K signaling (43).  
 
 PIP3 recruits Akt and phosphoinositide-dependent protein kinase 1 (PDPK1) to 
the membrane via their respective pleckstrin homology domain (1). The subsequent 
phosphorylation of Akt at T308 by PDPK1 and at S473 by mTORC2 results in full 
activation of Akt (44). Akt phosphorylates multiple important downstream targets 
including glycogen synthase kinase 3 beta (GSK3, forkhead box(Fox)O transcription 
factors, mouse double minute 2 homolog (Mdm2), Bcl-2-associated death promoter 
(BAD) and p27KIP1, together promoting survival and cell cycle entry (45). Akt also 
phosphorylates Tuberin, a guanosine triphosphate(GTP)ase-activating protein (GAP) for 
Ras homologue enriched in brain (Rheb). Phosphorylation of Tuberin results in its 
inactivation, allowing for GTP-bound Rheb to activate mTORC1 which regulates protein 
synthesis, RNA translation, cell growth and autophagy (46). In this manner, the 
PI3K/Akt/mTORC1 axis controls a diverse array of cellular processes and its 
overactivation in tumor cells confers a significant growth and survival advantage. 
 
The PI3K/Akt/mTORC1 pathway is one of the most commonly altered signaling 
pathways in human cancer. Such alterations leading to increased activity of the pathway 
in tumor cells include loss of the tumor suppressor PTEN as well as mutation and/or 
amplification of p110 and p85 subunits; RTKs such as HER2, FGFR, EGFR; the PI3K 
interactor and activator Ras; and the PI3K effector Akt (44). Mutational loss or deletion 
of PTEN occurs in a diverse array of human cancers (40) and predictably mediates an 
increase in PI3K signaling in PTEN-null tumor cell lines and primary tumors (47). The 
most common alterations of the pathway however occur within the helical domain 
(E542K and E545K) and kinase domain (H1047R) of p110. Helical domain 
mutations increase PI3K activity by diminishing the allosteric inhibition of p85 on the 
p110 subunit (48) or increasing interaction between p110 and insulin receptor 
substrate 1 (IRS-1) (49), while mutations in the kinase domain increase retention of 
p110 at the plasma membrane (50). Like helical domain alterations, mutations in p85 
reduce its ability to inhibit the p110 catalytic subunit (51, 52). As the canonical signaling 
through RTKs occurs through PI3K, the overexpression or constitutive activation of 
oncogenic RTKs such as HER2, FGFR, EGFR results in constant activation of the 
PI3K/Akt/mTORC1 pathway. Similarly, PI3K is activated canonically by Ras through 
direct binding to its Ras-binding domain and oncogenic overexpression of Ras results in 
constitutive PI3K activation. Regardless of the mechanism, hyperactivation of the 
pathway results in a significant advantage to tumor cells, promoting cell growth, division, 
protein synthesis and survival. In addition, the PI3K/Akt/mTORC1 pathway plays a 
major role in the metabolic rewiring observed in tumor cells.  
 
 The PI3K/Akt/mTORC1 pathway, under physiological activation by growth 
factors, mediates an important shift in the cell’s metabolic profile to an anabolic one. This 
allows the cell to coordinate its cellular metabolism to support bioenergetically 
demanding processes stimulated by growth factors. However, when constitutively 
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activated, the same downstream metabolic effects, as well as cancer specific ones, 
contribute to the altered metabolism observed in tumor cells. The PI3K effector Akt 
increases glucose transporter localization to the membrane (53) and phosphorylates HK2, 
increasing its activity (54). Akt also phosphorylates phosphofructokinase-2 (PFK2), 
enhancing its activity and increasing the levels of phosphofructo-2,6-bisphosphate, a 
potent allosteric activator of the key glycolytic enzyme PFK1 (55). As described above, 
Akt activates the downstream serine/threonine kinase mTORC1 complex. mTORC1 
induces expression of HIFs (56) which increase glycolytic flux as described in the 
previous section.  
 
Additionally, the upregulation of pyruvate kinase muscle isozyme 2 (PKM2) by 
mTORC1 is essential to aerobic glycolysis and tumor growth and occurs via its induction 
of HIF1 and Myc (57). There are two isoforms of M type pyruvate kinase which catalyze 
the dephosphorylation of phosphoenolpyruvate to pyruvate in the last step of glycolysis. 
While PKM1 is expressed in most terminally differentiated tissues, PKM2 is expressed in 
embryonic and proliferating tissues which require anabolic biosynthesis (15). The switch 
from oxidative phosphorylation to aerobic glycolysis in cancer cells reflects a shift from 
PKM1 to PKM2 expression (58) as the PKM2 exists in its inactive dimeric form in tumor 
cells, allowing for the accumulation of glycolytic intermediates for their use in 
biosynthesis (59) and entry into the pentose phosphate pathway (discussed in the next 
section). In this manner, constitutive activation of the PI3K/Akt/mTORC1 pathway 
contributes significantly to the metabolic rewiring observed in tumor cells while 
concomitantly promoting protein synthesis, cell growth, survival and division. 
 
 As one of the most commonly mutated signaling pathways across all human 
cancers, the PI3K/Akt/mTORC1 pathway controls a diverse array of essential cellular 
functions and thus is an important focus of current drug research. Excessive signaling 
through the pathway mediates the altered glycolytic metabolism observed in tumor cells, 
and as discussed in the next chapter, also facilitates an upregulation of the closely linked 
pentose phosphate pathway. 
 
 
The Pentose Phosphate Pathway and Cancer 
 
The pentose phosphate pathway (PPP) is a glucose catabolic pathway, tightly 
linked to glycolysis, that generates NADPH and ribose-5-phosphate (R5P) (Figure 1-2) 
and is upregulated in tumor cells. Glucose upon entering the cell is phosphorylated by 
hexokinase to glucose-6-phosphate (G6P) which can be further metabolized by 
glycolysis. G6P can also be dehydrogenated by glucose-6-phosphate dehydrogenase 
(G6PD) and enter the pentose phosphate pathway. The PPP is comprised of oxidative and 
nonoxidative branches. The former catalyzes the irreversible conversion of G6P to R5P 
and produces 2 molecules of NADPH in the process. NADPH is an important molecule 
necessary for reductive biosynthesis reactions and functions as a key reducing agent to 
counteract reactive oxygen species (ROS). R5P, a precursor to various biomolecules 
including nucleotides, can enter the nonoxidative, reversible branch of the PPP and be  
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Figure 1-2. Glycolysis and the pentose phosphate pathway are tightly linked 
glucose catabolic pathways. 
Glucose enters the cell via a glucose transporter and is subsequently phosphorylated by 
hexokinase (HK) to glucose-6-phosphate (G6P). G6P can be further catabolized by the 
glycolytic pathway (black arrows). G6P can also enter the oxidative arm of the PPP, 
which generates NADPH, an important biomolecule necessary for reductive biosynthesis 
and to counteract reactive oxygen species. The oxidative arm of the PPP generates 
ribulose-5-phosphate which can then enter the non-oxidative arm of the PPP to generate 
other intermediate biomolecules including the ribose-5-phosphate, a necessary precursor 
for nucleotide synthesis. As shown, the glycolytic and pentose phosphate pathways are 
tightly linked as glycolytic intermediates can enter the PPP and vice versa. 
Abbreviations: phosphofructokinase-1 (PFK1), pyruvate kinase (PK), glucose-6-
phosphate dehydrogenase (G6PD), transketolase (TKT).  
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converted into the glycolytic intermediates glyceraldehyde 3-phosphate (G3P) and 
fructose-6-phosphate (F6P). In this manner, glycolysis and the PPP are coordinated to 
meet the metabolic demands of the cell. Under oxidative stress, when greater levels of 
NADPH are required, R5P can be converted to G3P and F6P which in turn can be used to 
generate G6P (via gluconeogenic pathways) feeding the oxidative arm of the PPP and 
generating reductive NADPH (5). Likewise, the glycolytic intermediates G3P and F6P 
can enter the nonoxidative branch to generate R5P for nucleotide synthesis. Like 
glycolysis, higher PPP flux has been observed in various human cancers (5) and plays an 
important role in tumor proliferation, survival, invasion, drug resistance and metastasis 
(60). An increase in PPP flux supports the biogenesis of nucleotides while also generating 
NADPH necessary to synthesize lipids and other biomolecules as well as to counteract 
the high ROS present in tumor cells.  
 
 The PPP is frequently upregulated in various human cancers (60) and is 
presumably mediated by genetic alterations in the tumor suppressors p53 and PTEN and 
the oncogenic PI3K/Akt/mTORC1 activation. As the first and rate-limiting enzyme of the 
PPP, G6PD determines PPP flux and the upregulation of its expression and activity 
supports the bioenergetic demands of proliferating cancer cells (5). G6PD exists in either 
an inactive monomeric or active dimeric form. The tumor suppressor p53 has been 
previously shown to directly bind G6PD and prevent its dimerization while a cancer-
associated mutation of p53 was unable to inhibit G6PD activity (61). The oncogene K-
Ras stimulates glycolysis and drives glycolytic intermediates into the nonoxidative arm 
of the PPP in pancreatic ductal adenocarcinoma (62). The transcription factor HIF1 in 
addition to its upregulation of glycolytic enzymes also enhances G6PD expression (63). 
The PI3K/Akt downstream effector mTORC1 has also been shown to increase G6PD 
expression via induction of sterol regulatory element-binding protein (SREBP) 
transcription factors (56). The tumor suppressor PTEN, which negatively regulates PI3K 
signaling, appears to also have a role in suppressing G6PD activity (64). The loss of 
PTEN which occurs in a diverse array of tumors would therefore predictably increase 
PPP flux.   
 
 Collectively, the progressive accumulation of such genetic alterations that mediate 
the transformation of a normal cell to a cancerous one facilitate an altered metabolic 
phenotype characterized by increased aerobic glycolysis and PPP flux. Together, the 
upregulation of these glucose catabolic pathways provides energy and important 
intermediates to support the biogenesis required for rapid growth and proliferation. We 
hypothesize here that the altered metabolism of cancer cells not only provides precursors 
for anabolic biomass accumulation, but also generates signaling metabolites that regulate 
key cellular processes to further promote tumor growth and survival. Described in the 
next section, we have previously identified a novel metabolic regulation of apoptosis 
mediated by increased PPP flux generating coenzyme A, a novel signaling metabolite in 
our model.   
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Metabolic Regulation of Programmed Cell Death 
 
Studying altered metabolism in mammalian cells is cumbersome given the 
impermeability of most intermediate metabolites. The Xenopus oocyte system however 
has been shown by our group and suggested by others to be a more biochemically 
tractable model system providing insights into tumor cell metabolism (59, 65). Indeed, 
the metabolism of the Xenopus oocyte shares interesting similarities with the altered 
metabolism of tumor cells including increased lactate production, similar PK activity, the 
use of glutamine as a carbon source, and flux through the pentose phosphate pathway 
(59).  
 
 Using this biochemically robust model system, we have characterized a novel 
metabolic regulation of cell death mediated by increased flux through the PPP. G6P 
addition to Xenopus extract, mimicking aberrant glucose metabolism, via the pentose 
phosphate pathway leads to increased NADPH levels, subsequent increase in cytosolic 
acetyl-CoA and CaMKII activation (66-69). CaMKII in turn phosphorylates and inhibits 
caspase-2, blocking apoptosis. We recently identified coenzyme A, derived from the 
breakdown of acetyl CoA, as the key signaling metabolite that mediates a novel 
mechanism of metabolic activation of CaMKII (Figure 1-3). CoA binds directly to the 
regulatory CaMBD of CaMKII resulting in its activation (67). With these findings, we 
hypothesize that the altered concentration of acetyl CoA and CoA, generated by aberrant 
metabolism, contributes to the pathological activation of CaM-dependent enzymes 
contributing to diseases. To test this, we first took an unbiased approach to purify CaM-
binding proteins from Xenopus extract using a CaM-Sepharose column. Purified proteins 
were concentrated and next incubated with CoA-Sepharose, resolved by SDS-PAGE and 
silver staining. The results indicate the presence of multiple CaM-binding proteins that 
also bind CoA and are potentially metabolically regulated by aberrant glucose signaling. 
In a targeted approach, we tested the metabolic regulation of the CaM-binding protein 
PI3K. We found that G6P or CoA addition to Xenopus extract activated Akt in a PI3K 
and PDPK-1 dependent manner. Furthermore, we show that CoA directly binds and 
activates PI3K. These findings suggest a novel function for calmodulin binding proteins 
regulated by metabolism through CoA binding and uncover a potentially unknown 
mechanism of constitutive activation of PI3K by aberrant glucose metabolism in tumor 
cells. 
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Figure 1-3. A model of the noncanonical activation of CaMKII by altered glucose 
signaling.  
We have previously characterized a novel metabolic activation of CaMKII. Aberrant 
glucose metabolism leads to an increase in G6P which via the pentose phosphate pathway 
and increased NADPH levels, leads to an increase in cytosolic CoA levels. CoA, as a 
novel signaling metabolite in our model, binds directly to the CaMBD within the 
regulatory domain of CaMKII, resulting in a loss of secondary structure. Basal 
(nanomolar) Ca2+/CaM is then able to bind the CaMBD of CaMKII, displacing CoA and 
resulting in CaMKII autophosphorylation and activation. 
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CHAPTER 2.    MATERIALS AND METHODS 
 
 
Reagents 
 
Reagents were used as previously described (66-68). CaM-Sepharose was 
purchased from GE Healthcare Life Sciences (Cat #17052901). CaM column was made 
by packing CaM-Sepharose in a BioRad poly-prep chromatography column (Cat #731-
1550) to a final, packed bead volume of 1 mL. Purified CaM proteins from the column 
were concentrated and buffer exchanged using a 10K Ultra-15 centrifugal filter 
(Amicon, Cat #UFC501096). Recombinant p110/p85 was purchased from Sigma-
Aldrich (Cat #I1036). Extract was supplemented with phosophatidylinositol 
polyphosphates purchased from Echelon Biosciences Inc: D-myo-Phosphatidylinositol-
4,5-bisphosphate diC16 (PIP2-16) (Cat #P-4516), D-myo-Phosphatidylinositol-3,4,5-
trisphosphate diC16 (PIP3-16) (Cat #P-3916), or D-myo-Phosphatidylinositol-4,5-
bisphosphate diC8 (PIP2-8) (Cat #P-4508). 
 
D-myo-Phosphatidylinositol 4,5-bisphosphate 18:0/20:4 (Echelon Biosciences 
Inc, Cat #P-4524) was used as substrate in the PI3K thin-layer chromatography (TLC) 
assays. D-myo-Phosphatidylinositol 3,4,5-triphosphate 18:0/20:4 (Echelon Biosciences 
Inc, Cat #P-3924) was used as a standard in the PI3K TLC assays as the unsaturated 
fatty acid allows for identification by iodine vapor exposure. Wortmannin (Cat 
#10010591) and LY-294002 (LY) (Cat #70920) were purchased from Cayman 
Chemical. GSK2334470 (GSK) was purchased from AdooQ BioScience (Cat 
#A12767). 
 
Antibodies 
 
Calcium/calmodulin-dependent protein kinase IV (CaMKIV) rabbit polyclonal 
antibody with dog (Dg), human (H), mouse (M), Xenopus (X) reactivity was purchased 
from ThermoFisher Scientific Pierce (Cat #PA1-542, Lot #NE170396). CaMKII mouse 
monoclonal antibody with H, M, Dg, X reactivity was purchased from BD Biosciences 
(Cat #611292, Lot #5037692). PI3K p110 rabbit monoclonal antibody, H specificity 
(Cat #3011, Lot #6), p-T308-Akt rabbit polyclonal antibody, M specificity with cross 
reactivity against H, rabbit (R), hamster (Hm) (Cat #9275, Lot #’s 20, 21), p-S473-Akt 
rabbit polyclonal antibody, M specificity with cross reactivity against H, R, pig (Pg), 
Hm, bovine (B), Drosophila melanogaster (Dm), Dg, monkey (Mk), chicken (C), horse 
(Hr), X (Cat #9271, Lot #14) were purchased from Cell Signaling Technology. 
Calcineurin A rabbit polyclonal antibody with H, M, X reactivity (Cat #ab71149), Akt 
1/2/3 rabbit polyclonal antibody, H specificity with cross reactivity against M, R (Cat 
#ab126811), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mouse monoclonal 
antibody, H specificity with cross reactivity against M, R, C, B, Dg, Pg, X, Hm (Cat 
#9484, Lot #GR165366-1), and actin rabbit polyclonal antibody, H specificity with 
cross reactivity against M, R, C, B, X, Dm (Cat #ab1801) were purchased from Abcam. 
P110 rabbit polyclonal antibody, H specificity with cross reactivity against M, R, X, 
Hr, Dg, B (Cat #7174, Lot #G0214) and p85 rabbit polyclonal, H specificity with 
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cross reactivity against M, R, X, Hr, Dg, B, Pg (Cat #423, Lot #G1114) were purchased 
from Santa Cruz Biotechnology.  
 
 
Preparation of Xenopus Extract and Extract Cytosol 
 
 Mature female Xenopus laevis frogs were induced to lay eggs as previously 
described (70). Egg extracts and extract cytosol were prepared as previously described 
(68).  
 
 
Peptide Synthesis and Sepharose Coupling 
 
 All peptide synthesis and coupling was performed by the Macromolecular 
Synthesis Laboratory Core at St. Jude Children’s Research Hospital. For the tandem 
purification described in Chapter 3, CoA was coupled to Sepharose via the primary amine 
on the adenine ring. Phospho-tyrosine peptide [KKHTDDGY*MPMSPGVA] (pIRS), 
derived from mouse insulin receptor substrate 1 (IRS1), was synthesized and coupled 
covalently to Sepharose 4B at its NH2 terminus via a hexanoic acid linker. In Chapter 4, 
CoA was coupled to Affi-Gel 15 via the primary amine on the adenine ring. Glycine was 
coupled to Affi-Gel 15 and used as Affi-Gel 15 control beads where indicated. 
 
 
CoA/CaM Tandem Purification 
 
 CaM/CoA interactors were purified from Xenopus extract as follows (Figure 
2-1). CaM-Sepharose was packed in a chromatography column (BioRad Cat #731-1550) 
to a final bead volume of 1 milliliter (mL). The CaM column was equilibrated with 50 
millimolar (mM) tris(hydroxymethyl)aminomethane-hydrochloric acid (Tris-HCl) pH 7.5 
containing 150 mM sodium chloride (NaCl), and 2 mM calcium chloride (CaCl2). 
Xenopus egg extract was then bound to the column by gravity flow and washed with 50 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5 containing 1 
mM magnesium acetate (MgAc), 1 molar (M) NaCl, and 1 mM CaCl2. A second wash 
was then performed with 50 mM HEPES pH 7.5, 1 mM MgAc, 150 mM NaCl and 500 
micromolar (M) CaCl2. Proteins were eluted with 20 mM ethylene glycol-bis(β-
aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 1 M NaCl in 50 mM HEPES pH 
7.5. The column was regenerated with 50 mM Tris-HCl pH 7.5, 1 M NaCl and .1% triton, 
heated to 37 degrees Celsius, and stored in equilibration buffer containing 20% ethanol 
preservative. Eluted proteins were concentrated, buffer exchanged with 50 mM HEPES 
pH 7.5, and incubated with either CoA-Sepharose or Sepharose for 30 minutes at room 
temperature. Beads were washed, resolved by SDS-PAGE and either immunoblotted 
(along with samples of elution fractions) for CaMKII or silver stained. 
 
 Silver staining was performed by first fixing the SDS-PAGE gel in 10% acetic 
acid/ 30% ethanol for 2 hours. The gel was then rinsed with 20% ethanol for 20 minutes,  
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Figure 2-1. Tandem purification of CaM/CoA binding proteins from Xenopus egg 
extract.  
Xenopus egg extract was bound to a CaM-Sepharose column by gravity flow, washed and 
eluted with EGTA. Purified CaM-binding proteins were concentrated, buffer exchanged, 
and incubated with either CoA-Sepharose or Sepharose for 30 minutes at room 
temperature (RT) and resolved by SDS-PAGE. Gels were then either immunoblotted for 
the known CoA/CaM interactor CaMKII or silver stained.  
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ouble distilled water (ddH2O) for 10 minutes and then incubated with .2 gram (g)/ liter 
(L) sodium thiosulfate for 1 minute. After washing three times with ddH2O for 20 
seconds, 2 g/L silver nitrate was added for 45 minutes, followed by 5 rinses with ddH2O 
for 10 seconds each. Proteins were visualized by developing with 50 g/L sodium 
carbonate, 10 mg/L sodium thiosulfate, .25 mL/L 37% formaldehyde. Silver staining was 
stopped by adding 50 g/L Tris-base, 2.5% acetic acid and subsequently washed with 
ddH2O. 
 
 
PI3K TLC Assays and Spot Quantification 
 
 Direct PI3K thin layer chromatography (TLC) assays were performed as 
previously described (71) using 14 nM recombinant p110/p85 in 50 mM HEPES 
buffer with 5 mM magnesium chloride (MgCl2), 100 M ATP, 24 ng/L PIP2 18:0/20:4 
and 70 nCi/L [-32P]ATP. Reactions were run for 20 min at RT and resolved by TLC in 
n-propanol:water:acetic acid (64:33:2, v/v). A TLC assay was similarly performed using 
extract cytosol supplemented with 100 ng/uL PIP2 18:0/20:4, G6P with and without 
Wortmannin or LY. Samples were resolved by TLC in chloroform:methanol:water:acetic 
acid (10:10:3:1, v/v). Spot intensities were quantified using imageJ (72). Briefly, film 
exposures from independent experiments and within a linear range of exposure were 
scanned, adjusted to grayscale, and opened with imageJ. The rectangular tool was used to 
encompass radiograph spots, assigned by pressing [Ctrl+1], then spot intensities were 
plotted by pressing [Ctrl+3], peaks were isolated using the line segment tool, the area 
under each peak was measured using the wand (tracing) tool and each divided by the 
corresponding control (PI3K alone) area for each independent experiment. Averages 
across the experiments were plotted with standard deviation error bars. Statistical analysis 
was performed using paired t-test of each treatment compared to the corresponding PI3K 
alone control. 
 
 
Depletions of Egg Extract and Coupled-Sepharose Binding Assays 
 
Depletions of egg extract and affinity binding assays were performed as described 
previously (66, 68). PI3K in vitro affinity binding assays were performed by incubating 
CaM-Sepharose, pIRS-Sepharose, Sepharose alone, CoA-coupled Affi-Gel 15 or Affi-
Gel 15 control beads in 50 mM Hepes buffer with 14 nM recombinant p110/p85 for 30 
minutes at RT. Beads were washed 5 times with 1 mL of 500 mM NaCl/.5% triton, 
resolved by SDS-PAGE and immunoblotted for p110. 
 
 
HeLa Cell Cytosol Binding Assay 
 
 HeLa S3 cells, derived from human cervical adenocarcinoma (ATCC CCL-2.2) 
were grown to 80% confluency, trypsinized and homogenized in 20 mM HEPES buffer 
with 10 mM potassium chloride (KCl), 1.5 mM MgCl2, 1 mM Ethylenediaminetetraacetic 
acid (EDTA), 1 mM EGTA and 250 mM sucrose. Cells were pelleted and supernatant 
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removed. Equal volume of cell cytosol was then used in a CoA-Affi-Gel binding assay as 
described above. 
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CHAPTER 3.    IDENTIFICATION OF NOVEL COA/CAM INTERACTORS 
 
 
Introduction 
 
 Calmodulin binding proteins represent a diverse array of proteins involved in 
major cellular processes including metabolism, muscle contraction, cell death, memory 
and inflammation (73). We have previously characterized a novel metabolic activation of 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) mediated by direct CoA binding 
to its CaMBD (67). In our model, direct CoA binding results in a loss of secondary 
structure in CaMKII, facilitating basal (nanomolar) Ca2+/CaM binding and subsequent 
CaMKII autophosphorylation and activation (Figure 1-3). Given the great number of 
CaM interacting proteins that exist, we asked here if there are other CaM-binding 
proteins that also bind CoA and are thus potentially regulated by altered metabolic 
signaling.  
 
CaM is a relatively small, approximately 17 kilodalton (kDA), -helical protein 
comprised of N- and C-terminal lobes connected by a highly dynamic and flexible linker 
(74). While both lobes each contain two Ca2+ binding EF-hand motifs, the C-terminal 
lobe coordinates Ca2+ with a 10-fold greater affinity (Kd = 1 M) as compared to the N-
terminal lobe (Kd = 10 M) (75, 76). Given this and the Ca2+ cooperativity that exists 
both within and between its lobes, CaM has evolved to respond over a wide range of 
changes in cellular calcium concentrations (74). Upon Ca2+ binding, conformational 
changes in CaM expose hydrophobic patches in each lobe that facilitate binding to key 
hydrophobic residues in the CaMBD of target proteins (74). The large number of flexible 
methionine residues within these hydrophobic patches, in combination with the dynamic 
linker connecting the two lobes, allows for CaM to interact with a diverse set of proteins 
(77).  
 
While a defined CaM-binding consensus sequence does not exist, Ca2+/CaM-
binding sequences share important similarities including high helix propensity, a high 
density of positively charged residues and two hydrophobic anchor residues (73). The 
spacing of these two key hydrophobic residues within the approximately 20 amino acid 
CaM-binding domain allows for the classification of Ca2+/CaM-binding proteins into 
three groups (1-10, 1-14, and 1-16) (78). Adding to the complexity, CaM can bind its 
target proteins in either a parallel or anti-parallel orientation, depending on the charge 
density of the binding motif (77). Furthermore, CaM also interacts with target proteins in 
the absence of calcium via binding to the IQ motif (IQXXXRGXXXR) (75). Given this 
dynamic and promiscuous nature of its binding, CaM has been reported to bind over 300 
proteins (79-81). 
 
Given our previous results demonstrating that CoA directly binds to the CaMBD 
of CaMKII, a 1-10 CaM-binding protein, we asked here if there exist other CaM-binding 
proteins that also bind CoA and are thus potential targets of aberrant glucose signaling. In 
an unbiased, tandem purification approach, we identify the presence of numerous CaM-
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binding proteins that also bind CoA. These findings suggest a ubiquitous function for 
calmodulin binding proteins that also bind CoA and facilitate their metabolic regulation.  
 
 
Results 
 
 
CaM-binding proteins are efficiently purified from Xenopus extract 
 
 Given its high binding affinity and specificity for Ca2+/CaM, the CaMBD is 
classically used in combination with the calcium chelator EGTA to efficiently purify 
recombinantly expressed CaMBD-tagged proteins. Typically, tagged proteins are bound 
in the presence of calcium to calmodulin resin which is then washed in the presence of 
calcium and salt to reduce nonspecific binding. Bound proteins are eluted by removing 
Ca2+ with EGTA. In this manner, unbiased purifications of calmodulin-binding proteins 
from various cell-based systems have also been performed. Here, we developed a 
purification of calmodulin-binding proteins from Xenopus egg extract.  
 
The high concentration of proteins (50-60 g/L) and the ease by which we can 
generate large volumes by simply injecting a greater number of frogs to lay eggs renders 
the Xenopus oocyte model system as an ideal one to purify and examine protein-protein 
interactions. Here, we performed a tandem two-step purification of proteins from 
Xenopus extract using CaM-Sepharose and CoA-Sepharose (Figure 2-1). Xenopus 
extract was first bound to a CaM-Sepharose column by gravity flow. Bound proteins 
were washed and fractions were eluted with EGTA. Samples of fractions were taken, 
resolved by SDS-PAGE and immunoblotted for CaMKII as a reporter of the two-step 
purification. CaMKII was effectively eluted in the first five fractions (Figure 3-1A, left 
lanes). Fractions were combined, protein quantified and incubated with CoA-Sepharose 
or Sepharose. Beads were isolated, washed, resolved by SDS-PAGE and immunoblotted 
for CaMKII. Our two-step tandem purification was validated by the ability of CoA-
Sepharose to specifically and efficiently bind CaMKII from the pool of proteins eluted 
off the CaM-Sepharose column (Figure 3-1A, last two lanes). These results verify our 
developed protocol to purify CaM/CoA binding proteins and establish the Xenopus 
extract as a useful model system to isolate and study CaM-binding proteins. 
 
 
Numerous CaM-binding proteins exist that also bind CoA 
 
 As a bona fide interactor of both CaM and CoA, CaMKII was used as a reporter 
and validated our two-step purification described above. To visualize the existence of 
other CaM/CoA interactors, CaM-binding proteins were purified from Xenopus extract, 
concentrated, quantified and incubated with CoA-Sepharose as described above. Beads 
were washed, resolved by SDS-PAGE and silver stained. Relying on the reductive 
precipitation of silver ions complexed with amino acids, silver staining is highly sensitive 
allowing for the detection of less than 1 ng of protein (82). Here, silver staining revealed  
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Figure 3-1. Purification of CaM/CoA interactors from Xenopus extract. 
A, Xenopus extract was bound to a CaM-Sepharose column, washed, and eluted with 
EGTA. Fractions were resolved by SDS-PAGE and immunoblotted for CaMKII. Eluted 
fractions were combined, concentrated, quantified and incubated with either Sepharose or 
CoA-Sepharose for 30 minutes at RT, washed, resolved by SDS-PAGE and 
immunblotted for CaMKII. As a reporter of the tandem purification, CaMKII was 
successfully purified using the CaM-Sepharose column (left lanes) and subsequently 
effectively precipitated by CoA-Sepharose (last two lanes on right). n=3. B, Eluted CaM-
binding proteins were incubated with Sepharose or CoA-Sepharose as in A and resolved 
by SDS-PAGE followed by silver staining. Numerous CaM-binding proteins that also 
bind CoA are indicated by black arrows. n=3. 
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the existence of numerous CaM-binding proteins that also bind CoA (Figure 3-1B). In 
combination with our previously delineated model of metabolic activation of CaMKII 
mediated by direct CoA binding, these results suggest a novel function of CaM-binding 
proteins that also bind CoA and facilitate their regulation by altered glucose signaling.  
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CHAPTER 4.    METABOLIC ACTIVATION OF PHOSPHATIDYLINOSITOL 3-
KINASE 
 
 
Introduction 
 
Using the biochemically tractable Xenopus oocyte system, we have previously 
identified a novel metabolic regulation of pluripotent kinase Ca2+/calmodulin-dependent 
kinase II (CaMKII). We found that glucose-6-phosphate (G6P) via the pentose phosphate 
pathway leads to increased NADPH levels, subsequent increase in cytosolic acetyl CoA 
and CaMKII activation (66-69). We recently identified coenzyme A (CoA), derived from 
the breakdown of acetyl CoA, as the key metabolic signal that mediates a novel 
mechanism of CaM-dependent activation of CaMKII. CoA binds directly to the 
regulatory calmodulin binding domain of CaMKII resulting in its activation (67). With 
these findings, we hypothesize that the altered concentration of acetyl CoA and CoA, 
generated by aberrant metabolic flux, contributes to the pathological activation of CaM-
dependent enzymes resulting in disease. Analysis of proteins with CaM binding domains 
identified phosphatidylinositol 3-kinase (PI3K) as a potentially interesting target of our 
CoA-dependent, metabolic regulation. 
 
Class IA PI3K is canonically activated by receptor tyrosine kinase (RTK) 
transmembrane growth factor receptors (Figure 1-1). The phosphorylation of PIP2 to 
PIP3 by active class IA PI3Ks in the inner leaflet of the plasma membrane concomitantly 
recruits PDPK1 and Akt to the plasma membrane via their respective pleckstrin 
homology domain (1). Subsequent PDPK1-dependent phosphorylation of T308-Akt and 
the mTORC2-dependent phosphorylation of S473-Akt renders Akt fully active (44). With 
a pivotal role in tumor progression via its regulation of cell metabolism, growth, survival, 
motility, and differentiation (40), the PI3K/Akt pathway and its constitutive activation in 
a multitude of human cancers represents an extraordinary focus of cancer research. 
 
Previously published work has shown that PI3K is activated by calmodulin in a 
calcium-dependent manner (83). Furthermore, a high affinity calmodulin binding 
sequence, mapped within the p110 catalytic subunit and conserved among the four class I 
PI3K isoforms with sequence similarities to known calmodulin-binding proteins, was 
shown to bind calmodulin with a reported affinity constant of 5 nM (84).  
 
In this study, we tested if PI3K is metabolically regulated by CoA generated by 
glucose metabolism. We found that G6P, mimicking aberrant glucose metabolism, or 
CoA addition to Xenopus laevis egg extracts, activated Akt in a PI3K, PDPK1-dependent 
manner. Furthermore, we demonstrate that CoA can directly bind as well as directly 
activate PI3K. These findings uncover a novel mechanism of PI3K activation and a 
potential link between aberrant glucose metabolism and constitutive activation of 
PI3K/Akt in tumor cells. 
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Results 
 
 
CaM directly binds PI3K 
 
Previously published data identified a calmodulin binding sequence within the 
p110 catalytic subunit of PI3K. A 20-amino acid peptide derived from this putative 
CaMBD within the p110 isoform (Figure 4-1A) was shown to bind calmodulin (84). To 
determine whether CaM interacts with full length PI3K, we developed an affinity 
precipitation assay. The phospho-tyrosine Y608 peptide [KKHTDDGY*MPMSPGVA] 
(pIRS), derived from mouse insulin receptor substrate 1 (IRS1), has been previously 
shown to bind the SH2 domain of the regulatory p85 subunit of PI3K, resulting in 
activation of the enzyme (85). To establish an affinity precipitation assay for PI3K, pIRS 
peptide was immobilized on Sepharose and incubated with recombinant p110/p85 
PI3K. Figure 4-1A demonstrates that the control pIRS peptide directly interacted with 
recombinant PI3K. To confirm that CaM is a bona fide interactor of PI3K, we tested 
whether CaM-Sepharose affinity precipitates PI3K in vitro. While p110 is exclusively 
activated downstream of G-protein coupled receptors (GPCRs), the ubiquitously 
expressed p110 isoform has been shown to be activated downstream of both RTKs and 
GPCRs (13). Given this and the 100% conservation of key hydrophobic residues within 
the CaMBD of p110, , and  (Figure 4-1A), we chose to look at p110 as a 
representative of class IA PI3Ks. CaM-coupled Sepharose was incubated with 
recombinant p110/p85 PI3K, washed and resolved by SDS-PAGE. Figure 4-1B 
demonstrates that calmodulin directly bound PI3K p110/p85. Our data both confirm 
and demonstrate that calmodulin directly binds PI3K. 
 
 
pIRS (Y608) induces Akt phosphorylation in Xenopus extract 
 
In the canonical activation of the PI3K signaling cascade by insulin, 
phosphorylated tyrosine residues within the adaptor protein IRS1 activate PI3K by 
binding to the SH2 domain of the regulatory p85 subunit, releasing its allosteric 
inhibition on the p110 catalytic subunit (86). Active PI3K then phosphorylates PIP2 to 
PIP3 which recruits PDPK1 and Akt via their respective pleckstrin homology domain, 
facilitating the PDPK1-dependent phosphorylation of T308-Akt (44) (Figure 4-2A). To 
establish the Xenopus egg extract as a plausible model to study PI3K/Akt activation, we 
first incubated pIRS peptide in extract and immunoblotted for p-T308-Akt. Extract was 
supplemented with PIP2 to ensure that it was not rate limiting in the assay. Interestingly, 
only incubation of long-chain PIP2 (PIP2-16) with the pIRS peptide resulted in T308-Akt 
phosphorylation (Figure 4-2B). The activation of PI3K/Akt by pIRS peptide was 
inhibited by the documented PI3K inhibitors, wortmannin (Wort) and LY294002 (LY) 
(87 and 88, respectively), as evaluated by p-T308-Akt immunoblot (Figure 4-2C and 
Figure 4-2D, respectively). The data here identifies the Xenopus extract as a novel tool to 
study the canonical activation of PI3K/Akt and thus allowed us to next examine the 
activation of PI3K/Akt in our established model of aberrant glucose signaling. 
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Figure 4-1. Calmodulin directly binds PI3K. 
A, Putative calmodulin-binding sequences found in class I PI3K catalytic subunit 
isoforms are aligned with known CBDs of Kir/Gem, Rad, calcium ATPase and smooth 
muscle myosin light chain kinase (smMLCK). Conserved, hydrophobic residues are 
highlighted in bold (85). B, CaM-Sepharose, pIRS-Sepharose or Sepharose alone were 
incubated with 14 nM recombinant human p110/p85 in 50 mM HEPES buffer. Beads 
and 5% input of each sample were immunoblotted for p110. n=3. 
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Figure 4-2. Aberrant glucose signaling activates Akt. 
A, Canonical activation of PI3K/Akt by p-T608-IRS1. B, Extract was incubated with 1 
g/L pIRS peptide in the absence and presence of indicated concentrations of long-
chain PIP2 (PIP2-16) or short-chain PIP2 (PIP2-8). Samples were taken at 30 minutes 
and immunoblotted for p-T308-Akt. n=3. C, 1 microgram (g)/L pIRS peptide + 20 uM 
long-chain PIP2 was incubated in extract in the absence and presence of 1 M 
wortmannin. Samples were taken at 30 minutes and immunoblotted for p-T308-Akt. n=3. 
D, Experiment was performed as in C with indicated concentrations of LY294002. n=3. 
E, Extract + 1 M PIP2-16 was incubated in the absence and presence of 20 mM G6P. 
Samples were taken at indicated times and immunoblotted for p-T308-Akt. n>3. F, 
Experiment was performed as in E and samples immunoblotted for p-S473-Akt. n=3. G, 
Extract was incubated in the presence of 20 mM G6P and indicated concentrations of 
long or short-chain PIP2. Control samples were extract alone, + 50 M long or 50 M 
short-chain PIP2. Samples were taken at indicated times and immunoblotted for p-T308-
Akt. n=3. H, Extract was incubated alone, in the presence of 20 mM G6P + indicated 
concentrations of long-chain PIP2, and in the presence of indicated concentrations of 
long-chain PIP3. Samples were taken at indicated times and immunoblotted for p-Akt 
T308. n=3. All n’s are of independent experiments.  
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Aberrant glucose signaling activates Akt 
 
Our previous work delineates a model of aberrant glucose signaling where 
addition of G6P results in an increase in cytosolic acetyl CoA levels and subsequently 
CoA levels via a yet undescribed metabolic pathway. CoA binds directly to CaMKII 
within the CaM binding domain, activating CaMKII (67). Given our results confirming 
PI3K as a CaM binding protein and establishing a working model of PI3K-dependent Akt 
activation in Xenopus egg extract, we next evaluated PI3K activation in the context of our 
established model of aberrant glucose signaling.  
 
Using phosphorylation of T308-Akt as a reporter of PI3K activity, extract was 
incubated with G6P and immunoblotted for p-T308- and p-S473-Akt. G6P-induced 
sustained phosphorylation of both T308- and S473-Akt (Figure 4-2E and Figure 4-2F). 
While G6P addition alone was sufficient to activate Akt, titration of the long chain, and 
not short chain PIP2, resulted in a dose-dependent increase in T308-Akt phosphorylation 
(Figure 4-2G), similar to pIRS peptide addition (Figure 4-2B). Furthermore, titration of 
another Akt activator, long-chain PIP3 resulted in a strong phosphorylation of T308-Akt 
(Figure 4-2H) similar to G6P (Figure 4-2G) whereas short-chain PIP3 did not (data not 
shown). While the activation of PI3K/Akt has been extensively studied under 
conventional growth factor stimulation, this is the first evidence that aberrant glucose 
metabolism, represented by G6P addition, is capable of activating PI3K and in turn Akt. 
Taken together, the data here establishes the Xenopus egg extract as a novel tool to study 
PI3K/Akt activation both in the context of canonical phospho-tyrosine peptide 
stimulation as well as our novel model of G6P-mediated aberrant glucose signaling.  
 
 
Aberrant glucose metabolic activation of Akt is PI3K- and PDPK1-dependent 
 
To confirm that the metabolic activation of Akt by G6P was indeed occurring via 
a novel metabolite-mediated activation of PI3K, T308-Akt phosphorylation was analyzed 
in the presence of G6P and two different PI3K inhibitors. Indeed, both wortmannin and 
LY inhibited the G6P-mediated phosphorylation of T308-Akt (Figure 4-3A and Figure 
4-3B). Next, we affinity depleted PI3K using two different methods. Extracts were 
incubated with either pIRS-Sepharose or CaM-Sepharose and serial depleted for PI3K. 
Figure 4-3C (left panel) and Figure 4-3D, demonstrate that both the pIRS peptide and 
CaM resins significantly depleted PI3K. Furthermore, the G6P-dependent metabolic 
activation of Akt was significantly abrogated in PI3K-depleted extract as compared to 
Sepharose-depleted control extract (Figure 4-3C, right panel, and Figure 4-3E). These 
results confirm that the G6P-mediated activation of Akt observed in extract is occurring 
via PI3K activation and thus supports our finding of a novel metabolic activation of 
PI3K/Akt.  
 
While phosphorylation of T308-Akt is indeed an accepted indicator of PI3K 
activity, it is nonetheless an indirect reporter. To look at endogenous PI3K activity 
directly, we performed a PI3K TLC kinase assay in Xenopus extract, looking at  
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Figure 4-3. Aberrant glucose metabolic activation of Akt is PI3K and PDPK1-
dependent.  
A, Extract + 1 M PIP2-16 was incubated in the absence and presence of 20 mM G6P 
and indicated concentrations of wortmannin. Samples were taken at indicated times and 
immunoblotted for p-T308-Akt. n>3. B, Experiment was performed as in A, with 
indicated concentrations of LY294002. n=3. C, Extract was affinity depleted using pIRS-
Sepharose or Sepharose. Depleted extracts were then incubated with pIRS-Sepharose for 
30 min at RT. Beads were immunoblotted for p110 and p85 (left panel). Depleted 
extracts were incubated with 1 M PIP2-16 in the absence and presence of 20 mM G6P 
and samples were taken at indicated times and immunoblotted for p-T308-Akt (right 
panel). n=3. D, CaM-Sepharose or Sepharose depleted extracts were incubated with 
pIRS-Sepharose for 30 min at RT and beads were immunoblotted for p110 and p85. 
n=3. E, CaM-Sepharose or Sepharose control depleted extracts + 1 M PIP2-16 were 
incubated in the absence and presence of 20 mM G6P. Samples were taken at indicated 
time points and immunoblotted for p-T308- and p-S473-Akt. n=3. F, Extract was 
incubated with 5 mM MgCl2, 100 M ATP, 70 nCi/L [-32P]ATP  with 100 ng/L PIP2 
alone or + 20 mM G6P +/- wortmannin or LY. All reactions were run for 20 min at RT 
and resolved by TLC in chloroform:methanol:water:acetic acid (10:10:3:1, v/v). n>3. G, 
20 mM G6P + 1 M PIP2-16, 2 M PIP3-16, or 1 g/L pIRS + 20 M PIP2-16 were 
each incubated in extract in the presence of indicated concentrations of GSK2334470 
(GSK). Samples were incubated for 30 min at RT and immunoblotted for p-T308-Akt. 
Negative control extract contained 20 M PIP2-16. n=3. All n’s are of independent 
experiments. 
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phosphorylation of the class IA PI3K substrate PIP2 18:0/20:4. Extract was incubated 
with [-32P]ATP and 100 ng/L PIP2 18:0/20:4 in the absence and presence of G6P with 
and without wortmannin or LY. Reactions were run for 20 minutes at room temperature 
and resolved by TLC in chloroform:methanol:water:acetic acid (10:10:3:1, v/v). G6P 
addition to the extract resulted in PI3K phosphorylation of PIP2 as measured by an 
increase in PIP3 production (Figure 4-3F). In addition, both wortmannin and LY 
inhibited the G6P-dependent PI3K phosphorylation of PIP2 (Figure 4-3F). We next 
tested if our novel metabolic activation of PI3K/Akt is PDPK1-dependent as is the case in 
its canonical activation. The PDPK1 inhibitor GSK2334470 (GSK) effectively blocked 
PI3K-dependent Akt activation by G6P as well as by PIP3 and pIRS peptide controls 
(Figure 4-3G). The results indicate PDPK1-dependent phosphorylation of T308-Akt is 
conserved in our novel metabolic regulation of PI3K-dependent Akt activation. 
Furthermore, both chemical or affinity reduction of PI3K inhibited PI3K/Akt activation 
by aberrant glucose metabolism. Finally, direct analysis of PI3K activity confirmed the 
metabolic activation of PI3K. 
 
 
CoA mediates a novel metabolic activation of PI3K/Akt 
 
Our previous work identified a G6P-pentose phosphate pathway-AcetylCoA-CoA 
metabolic cascade resulting in the metabolic activation of CaMKII (67). However, 
aberrant glucose signaling (as mimicked by G6P addition) may have direct or indirect 
effects resulting in PI3K/Akt activation. To determine whether our novel metabolic 
activation of PI3K/Akt occurs in a similar fashion, we treated extracts with a 
nonmetabolizable 2-deoxyglucose-6-phosphate (2D-G6P) and assayed PI3K activity by 
immunoblotting for p-T308-Akt. G6P induced phosphorylation of T308-Akt; however, 
addition of 2D-G6P had no effect (Figure 4-4A), indicating that G6P catabolism, 
mimicking aberrant glucose signaling, is responsible for the novel activation of 
PI3K/Akt. 
 
We next tested the ability of CoA, the key metabolic signaling cofactor in our 
model of aberrant glucose signaling, to activate endogenous PI3K. CoA addition to the 
extract in the presence of long-chain PIP2 activated PI3K-dependent T308-Akt 
phosphorylation as well as S473-Akt phosphorylation (Figure 4-4B and Figure 4-4C, 
respectively). Additionally, the PI3K inhibitors, wortmannin and LY, abrogated the CoA-
mediated metabolic activation of Akt in the extract (Figure 4-4D and Figure 4-4E, 
respectively). This novel CoA-dependent, metabolic activation of PI3K/Akt was also 
inhibited by GSK, again indicating conservation of the role of PDPK1 in PI3K-dependent 
Akt activation (Figure 4-4F). These findings corroborate CoA as the key metabolic 
signaling factor in our model of aberrant glucose signaling, mediating the novel 
metabolic activation of PI3K, in turn activating downstream Akt in a PDPK1-dependent 
manner.  
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Figure 4-4. CoA mediates a novel metabolic activation of PI3K/Akt. 
A, Extract was incubated in the absence or presence of 20 mM G6P or 20 mM 2-
deoxyglucose-6-phosphate (2D-G6P) and indicated concentrations of PIP2-16. Samples 
were taken at indicated times and immunoblotted for p-T308-Akt. n=3. B, Extract was 
incubated with 20 mM G6P or 10 mM CoA and indicated concentrations of PIP2-16. 
Samples were taken at indicated time points and immunoblotted for p-T308-Akt. n=3. C, 
Extract + 10 M PIP2-16 was incubated in the presence or absence of 10 mM CoA. 
Samples were taken at indicated time points and immunoblotted for p-S473-Akt. n=3. D, 
Extract + 10 M PIP2-16 was incubated in the absence and presence of 10 mM CoA and 
indicated concentrations of wortmannin. Samples were incubated at RT for 30 min and 
immunoblotted for p-T308-Akt. n=3. E, Experiment was performed as in D, with 
indicated concentrations of LY. n=3. F, 10 mM CoA + 10 M PIP2-16, 2 M PIP3-16, 
or 1 g/L pIRS + 20 M PIP2-16 were each incubated in extract in the presence of 
indicated concentrations of GSK2334470 (GSK). Samples were incubated for 30 min at 
RT and immunoblotted for p-T308-Akt. Negative control extract contained 20 M PIP2-
16. n=3. All n’s are of independent experiments. 
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CoA activation of Akt is PI3K-dependent 
 
The results presented thus far identify a novel CoA-mediated metabolic activation 
of PI3K/Akt. Given this and our previous work demonstrating that CoA binds the 
CaMBD and activates CaMKII, we hypothesized that CoA similarly binds and activates 
PI3K. First, CoA was immobilized on Affi-Gel via the primary amine of the adenine ring. 
Then, CoA-Affi-Gel was incubated in HeLa cell extracts, washed and resolved by SDS-
PAGE. CoA successfully affinity precipitated endogenous PI3K (Figure 4-5A). To 
further provide evidence that CoA binds PI3K, we tested whether serial affinity 
precipitations would efficiently deplete PI3K in Xenopus extract. To assay PI3K protein 
levels, depleted extracts were incubated with pIRS-Sepharose. Isolated complexes were 
resolved by SDS-PAGE and immunoblotted for endogenous PI3K. PI3K was 
significantly depleted in CoA-Affi-Gel depleted extracts (Figure 4-5B). Moreover, 
metabolic activation of Akt, as indicated by T308- and S473-Akt phosphorylation, was 
inhibited in PI3K-depleted extracts (Figure 4-5C).  These results demonstrate the ability 
of CoA to bind endogenous PI3K and corroborate our novel mechanism whereby 
aberrant glucose signaling, mediated by CoA, activates Akt in a PI3K-dependent manner. 
 
 
Coenzyme A directly binds and activates class I PI3K 
 
Given that CoA binds endogenous PI3K, we next determined whether CoA 
directly interacts with PI3K. Indeed, when CoA-Affi-Gel was incubated in buffer with 
recombinant p110/p85, washed and resolved by SDS-PAGE, CoA directly bound 
recombinant PI3K (Figure 4-5D). Since CoA directly bound to PI3K, we then evaluated 
the ability of CoA to directly activate PI3K. Recombinant p110/p85 activity was 
analyzed in the absence and presence of free CoA or pIRS peptide in a direct TLC kinase 
assay using 24 ng/L PIP2 18:0/20:4 as substrate with [-32P]ATP. Reactions were 
incubated for 20 min at room temperature in 50 mM HEPES buffer and resolved by TLC 
in n-propanol:water:acetic acid (64:33:2, v/v). Addition of CoA significantly increased 
PIP3 production by more than 3-fold as compared to basal PI3K activity (Figure 4-5E). 
Addition of pIRS peptide activated recombinant p110/p85 by a two-fold increase 
(Figure 4-5E). Furthermore, a titration of CoA significantly increased PI3K activity at 
physiologically relevant concentrations found in mammalian cells starting from 1mM to 
10 mM (Figure 4-5F). Taken together, this data demonstrates that CaM is not required 
for the novel metabolic activation of PI3K, and CoA, the pivotal metabolic signaling 
molecule in our model of aberrant glucose metabolism, directly binds to and activates a 
representative class IA PI3K, p110/p85. 
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Figure 4-5. Coenzyme A directly binds and activates class I PI3K. 
A, CoA-Affi-Gel or Affi-Gel control beads were incubated in HeLa cell cytosol. Beads 
and 10% input of each sample was immunoblotted for p110. n=3. B, CoA-Affi-Gel or 
Affi-Gel depleted extracts were incubated with pIRS-Sepharose for 30 min at RT and 
beads were immunoblotted for p110 and p85. n=3. C, CoA-Affi-Gel or Affi-Gel 
control depleted extracts + 1 M PIP2-16 were incubated in the absence and presence of 
20 mM G6P. Samples were taken at indicated time points and immunoblotted for p-
T308- and p-S473-Akt. n=3. D, CoA-Affi-Gel or Affi-Gel were incubated in 50 mM 
HEPES buffer with 14 nM recombinant p110/p85. Beads and 5% input of each sample 
were immunoblotted for p110. n=3. E, A direct TLC kinase assay was performed in the 
absence and presence of 14 nM recombinant p110/p85 alone, +10 mM CoA, or +27.2 
g/L pIRS peptide; all in the presence of 24 ng/L PIP2 18:0/20:4, 5 mM MgCl2, 100 
M ATP, and 70 nCi/L [-32P]ATP. Reactions were incubated for 20 min at RT in 50 
mM HEPES buffer and resolved by TLC in n-propanol:water:acetic acid (64:33:2, v/v). 
PIP3 18:0/20:4 was run alongside, identified by iodine vapor exposure and its location 
marked on the TLC silica plate prior to autoradiography. PIP3 spot intensities for CoA 
and pIRS treatments were quantified, relative to PI3K alone, using imageJ software (72). 
Statistical analysis for CoA and pIRS was done using paired t-test, each relative to PI3K 
alone (CoA, p=.0003; pIRS, p=.0003). Standard deviation error bars are shown. n=5. F, 
Direct TLC kinase assay was repeated in the absence and presence of 14 nM recombinant 
p110/p85 alone, +.05, .5, 1, 5, or 10 mM CoA. PIP3 standard was run alongside 
samples as shown. Quantification and statistical analysis was done as in C (p<.0001 for 1 
mM CoA, p=.0013 for 5 mM CoA, p=.0105 for 10 mM CoA). Standard deviation error 
bars are shown. n=3. All n’s are of independent experiments.  
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CHAPTER 5.    DISCUSSION 
 
 
We previously characterized a novel G6P-NADPH-acetylCoA-CoA metabolic 
cascade resulting in the activation of CaMKII (66-69). CoA, the key metabolic signaling 
cofactor in our model of aberrant glucose signaling, directly binds and activates CaMKII 
(67). We postulated that CoA similarly interacts and metabolically regulates other CaM-
dependent enzymes. In the current studies, we demonstrate that numerous CaM-binding 
proteins bind CoA and identify PI3K as a specific, direct interactor of CoA, facilitating 
the metabolic activation of the PI3K/Akt pathway in a PDPK1-dependent manner. These 
findings uncover a novel mechanism of PI3K activation by aberrant glucose signaling 
and identify a potential process of constitutive activation of the PI3K pathway in tumor 
cells. 
 
CaM binds its client proteins in either a calcium dependent or independent 
manner. Ca2+-dependent calmodulin binding proteins can be further classified into three 
groups (1-10, 1-14, and 1-16) based on the spacing of bulky hydrophobic and basic 
amino acid residues within the 20 amino acid CaMBD (78). Our previous work 
demonstrated direct CoA binding to the CaMBD of CaMKII, a 1-10 calmodulin binding 
protein. As shown in Figure 4-1A, the putative CaMBD mapped within the p110 
catalytic subunit of PI3K contains hydrophobic residues conserved among the four class I 
PI3K isoforms and the 1-14 calmodulin binding proteins. The ability of CoA to directly 
bind and activate PI3K therefore extends our model of aberrant metabolic regulation to 
potentially include other 1-14 and 1-10 CaM-dependent enzymes. Indeed, our two-step 
tandem purification shown here demonstrates the existence of multiple CaM-binding 
proteins that also bind CoA. Furthermore, when CoA was immobilized on Affi-Gel 
matrix and incubated in Xenopus extract, Ca2+/calmodulin-dependent kinase IV and 
calcineurin were successfully precipitated (Figure 5-1) demonstrating that CoA binding 
CaMBD may be a novel locus of metabolic control for a subclass of calmodulin binding 
proteins. Given the conservation of hydrophobic residues in the primary sequences of 
Ca2+/calmodulin binding domains (53), these findings suggest a novel function for 
calmodulin binding proteins regulated by metabolism through CoA binding. 
 
Our current and previous findings support a new concept of metabolites/co-factors 
acting as important second messengers in cellular signaling. Increased levels of cytosolic 
acetyl-CoA have been detected in cancer. This emerging area of cancer biology is 
attracting attention as acetyl-CoA levels regulate general protein acetylation and 
specifically histone acetylation, in turn regulating gene transcription. Acetyl-CoA 
metabolism may therefore be a node of control for cancer epigenetics. Our finding that 
free CoA, generated from the breakdown of acetyl-CoA, regulates oocyte survival 
contributes to the concept of metabolites/co-factors directly regulating enzyme function. 
Furthermore, we have extended this model here to show that CoA binds multiple CaM-
binding proteins and metabolically activates PI3K. 
 
While CoA is sufficient to directly bind and activate PI3K in vitro, acetyl-CoA or 
another small-chain or long-chain acyl-CoA may be the relevant mediator of the   
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Figure 5-1. CoA binds endogenous CaMKIV and Calcineurin. 
A, Xenopus extract was incubated with CoA-Sepharose, CaM-Sepharose or Sepharose for 
30 minutes at RT. Beads were isolated, washed and immunoblotted for CaMKIV. n=2. B, 
Experiment was performed as in A with Sepharose or CoA-Sepharose and 
immunoblotted for calcineurin. n=2. 
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metabolic activation of PI3K/Akt in vivo. Long-chain acyl CoA derivatives have been 
shown to specifically activate the CaM-binding ryanodine receptor (89). Palmitoyl-CoA-
activated ryanodine channel was shown to be sensitive to calcium in the presence of 
inhibitory, millimolar concentrations of Mg2+ (89). Cytosolic levels of acetyl CoA are 
known to increase in conditions of anabolic states, cellular proliferation and 
differentiation (6). Acetyl-CoA, as a signaling metabolite, mediates the acetylation of 
proteins most notably histones, relaxing chromatin structure and ultimately inducing gene 
expression that promotes differentiation or proliferation (6). This allows the cell to 
coordinate such metabolically demanding processes with its metabolic state.  
 
The growth factor-dependent metabolic state of the cell may be regulated by the 
G6P-acetylCoA-CoA mediated activation of PI3K/Akt. The canonical activation of 
PI3K/Akt by growth factors results in Akt-mediated translocation of glucose transporters 
to the cell membrane, activation of hexokinase and phosphofructokinase-1 as well as the 
mTORC1-mediated upregulation of glycolytic enzymes and G6PD via HIF1 and Myc 
induction (53-56). This increased glucose metabolism is necessary to support 
differentiation and proliferation stimulated by growth factor signaling. The novel 
metabolic activation of PI3K/Akt described here may represent a feed-forward signal 
under physiological conditions that coordinates increased glucose metabolism with such 
bioenergetically demanding processes stimulated by growth factor signaling. However, 
under pathological conditions such as aberrant metabolism in cancer, this novel metabolic 
activation of PI3K/Akt may represent a new mechanism of constitutive activation of the 
pathway in tumor cells.  
 
Constitutive activation of PI3K/Akt occurs in a large, diverse number of human 
cancers primarily via mutation in the catalytic subunit p110 of class IA PI3K (90). 
About 80% of the mutations map to three hot spots substitutions, E542K and E545K in 
the helical domain and H1047R within the kinase domain (90). These mutations increase 
PI3K enzymatic activity, constitutively activate Akt, induce growth factor- and 
anchorage-independent growth in cell culture, and cause tumors in vivo (91-96). 
Biochemical and structural studies suggest that the E542K and E545K mutations relieve 
an inhibitory interaction between the N-terminal SH2 domain of the regulatory p85 
subunit and the helical domain of p110, resulting in constitutive kinase activity (97-99). 
Interestingly, the putative calmodulin binding domain mapped within the p110 catalytic 
subunit lies at the C-terminus of the helical domain. CoA direct binding to this CaMBD 
may result in a conformational change that likewise relieves the allosteric inhibition of 
the p85 regulatory subunit on the p110 catalytic subunit (Figure 5-2). In this fashion, 
aberrant glucose signaling generating CoA may act as an independent activator of PI3K 
or in the presence of these genetic mutations, direct CoA binding may synergistically 
augment PI3K activity. In this manner, as one of the defined hallmarks of cancer cells 
(3), aberrant metabolism generating increased cytosolic acetyl-CoA and CoA levels may 
coordinate a novel mechanism of constitutive activation of PI3K/Akt via direct CoA 
interaction.  
 
Studying altered metabolic regulation in mammalian cells is cumbersome given 
the impermeability of most intermediate metabolites. The Xenopus oocyte system has   
 35 
 
Figure 5-2. CoA directly binds and activates PI3K, mediating the novel metabolic 
activation of PI3K/Akt. 
Schematic of the novel metabolic activation of PI3K. Increased glucose metabolism via 
G6P fluxing through the PPP leads to increased cytosolic CoA levels. CoA directly binds 
to PI3K, potentially relieving the allosteric inhibition of the p85 subunit on the p110 
catalytic subunit. Active PI3K phosphorylates PIP2 to PIP3 which recruits PDPK1 and 
Akt, resulting in Akt phosphorylation and activation.  
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been shown by our group and suggested by others to be a more biochemically tractable 
model system providing insights into tumor cell metabolism (59, 65). Here, using the 
Xenopus oocyte model system allowed us to discover the existence of multiple CaM-
binding proteins that bind CoA as well as delineate a novel mechanism of PI3K/Akt 
activation by altered glucose signaling. A better understanding of the molecular 
mechanisms underlying this link could provide a viable therapeutic target applicable to 
many human cancers. 
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